GH Research PLC (NASDAQ:GHRS – Get Rating) shares saw unusually-high trading volume on Thursday . Approximately 19,172 shares changed hands during mid-day trading, a decline of 80% from the previous session’s volume of 94,597 shares.The stock last traded at $10.07 and had previously closed at $9.75.
GHRS has been the subject of a number of recent analyst reports. Roth Capital initiated coverage on shares of GH Research in a research note on Wednesday. They issued a “buy” rating and a $66.00 target price for the company. Canaccord Genuity Group lowered their target price on shares of GH Research from $45.00 to $41.00 and set a “buy” rating for the company in a research note on Wednesday, April 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $38.54.
The company has a market capitalization of $507.74 million and a PE ratio of -33.62. The business’s 50-day simple moving average is $13.07 and its 200-day simple moving average is $17.17.
Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of GH Research during the 4th quarter valued at approximately $113,000. Bank of America Corp DE increased its holdings in shares of GH Research by 31,790.0% during the 1st quarter. Bank of America Corp DE now owns 6,378 shares of the company’s stock valued at $116,000 after purchasing an additional 6,358 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in shares of GH Research during the 4th quarter valued at approximately $165,000. AdvisorShares Investments LLC increased its holdings in shares of GH Research by 278.0% during the 4th quarter. AdvisorShares Investments LLC now owns 14,242 shares of the company’s stock valued at $332,000 after purchasing an additional 10,474 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of GH Research during the 3rd quarter valued at approximately $380,000. 78.06% of the stock is owned by hedge funds and other institutional investors.
About GH Research (NASDAQ:GHRS)
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
- Get a free copy of the StockNews.com research report on GH Research (GHRS)
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
- A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market
- Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.